Nintedanib (BIBF 1120)

For research use only. Not for use in humans.

目录号：S1010 别名： Intedanib, Vargatef, Ofev 中文名称：尼达尼布

Nintedanib (BIBF 1120) Chemical Structure

CAS No. 656247-17-5

Nintedanib (BIBF 1120, Intedanib, Vargatef, Ofev) 尼达尼布是一种有效的三重血管激酶抑制剂，作用于VEGFR1/2/3， FGFR1/2/3和PDGFRα/β，在无细胞试验中IC50分别为34 nM/13 nM/13 nM， 69 nM/37 nM/108 nM和59 nM/65 nM。Phase 3。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1970.51	现货
5mg	RMB 991.25	现货
50mg	RMB 5492.96	现货
200mg	RMB 10401.3	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Nintedanib (BIBF 1120)发表文献87篇：

Nature, 2011, 12;478(7369):349-55.

PubMed: 21993628 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )

Mol Med Rep, 2021, 23(4):1

PubMed: 33495832 ( click the link to review the publication )

J Clin Invest, 2020, 130(2):942-957

PubMed: 31689244 ( click the link to review the publication )

Clin Cancer Res, 2020, 20 pii: clincanres

PubMed: 32312893 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Lab Chip, 2020, 10.1039/d0lc00252f

PubMed: 33103699 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Front Bioeng Biotechnol, 2020, 8:582602

PubMed: 33072731 ( click the link to review the publication )

Sci Rep, 2020, 10(1):19723

PubMed: 33184327 ( click the link to review the publication )

Acta Pharmacol Sin, 2020, 23

PubMed: 32327724 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Exp Eye Res, 2020, 194:108004

PubMed: 32184103 ( click the link to review the publication )

SLAS Discov, 2020, 19;2472555220915851

PubMed: 32425084 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Thorax, 2020, thoraxjnl-2019-214000

PubMed: 32709610 ( click the link to review the publication )

Mol Cancer Res, 2020, 18(4):549-559

PubMed: 31941753 ( click the link to review the publication )

Br J Cancer, 2020, 122(7):986-994

PubMed: 32015511 ( click the link to review the publication )

Nat Commun, 2019, 10(1-:2987

PubMed: 31278260 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2019, 101021/acsami9b20178

PubMed: 31816241 ( click the link to review the publication )

Thyroid, 2019, 29(3):395-404

PubMed: 30724135 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(6):1193-1203

PubMed: 31867165 ( click the link to review the publication )

J Clin Med, 2019, 8(3)

PubMed: 30841487 ( click the link to review the publication )
J Cancer, 2019, 10(4):1004-1012

PubMed: 30854106 ( click the link to review the publication )

J Virol, 2019, 10.1128/JVI.01791-19

PubMed: 31826996 ( click the link to review the publication )

PLoS Negl Trop Dis, 2019, 13(3):e0006959

PubMed: 30849083 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2019, 316(2-:L348-L357

PubMed: 30489156 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Am J Physiol Gastrointest Liver Physiol, 2019, 316(1-:G15-G24

PubMed: 30406699 ( click the link to review the publication )

Dig Dis Sci, 2019, 10.1007/s10620-019-05656-w

PubMed: 31102128 ( click the link to review the publication )

Cell Mol Bioeng, 2019, 12(5-:529-540

PubMed: 31719931 ( click the link to review the publication )

Nephron, 2019, 10.1159/000499506

PubMed: 31048591 ( click the link to review the publication )

Oncol Lett, 2019, 17(3-:3151-3162

PubMed: 30867745 ( click the link to review the publication )

Oncol Lett, 2019, 18(3):2220-2231

PubMed: 31452723 ( click the link to review the publication )

Anticancer Res, 2019, 39(6-:2739-2747

PubMed: 31177109 ( click the link to review the publication )

Nat Commun, 2018, 9(1-:2066

PubMed: 29802256 ( click the link to review the publication )

Cell Rep, 2018, 24(5-:1266-1277

PubMed: 30067981 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Angiogenesis, 2018, 21(4-:861-871

PubMed: 29967964 ( click the link to review the publication )

Respir Res, 2018, 19(1):175

PubMed: 30219058 ( click the link to review the publication )

Molecules, 2018, 23(8-

PubMed: 30087305 ( click the link to review the publication )

Nat Nanotechnol, 2018, 13(1-:72-81

PubMed: 29203914 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10-:2130-2143

PubMed: 28751539 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:2963

PubMed: 28592821 ( click the link to review the publication )

Sci Rep, 2017, 7(1-:9963

PubMed: 28855577 ( click the link to review the publication )
Sci Rep, 2017, 7(1-:5519

PubMed: 28717217 ( click the link to review the publication )

Sci Rep, 2017, 7:44545

PubMed: 28291245 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1147-1158

PubMed: 28435226 ( click the link to review the publication )

SLAS Discov, 2017, 22(5-:602-613

PubMed: 28346097 ( click the link to review the publication )

Oncol Lett, 2017, 14(1):944-950

PubMed: 28693256 ( click the link to review the publication )

Korean J Parasitol, 2017, 55(5): 491–503

PubMed: 29103264 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29050315 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Cancer Lett, 2016, 382(1):44-52

PubMed: 27569654 ( click the link to review the publication )

Front Cell Dev Biol, 2016, 4:114

PubMed: 27800477 ( click the link to review the publication )

Cancer Sci, 2016, 107(11-:1667-1676

PubMed: 27581340 ( click the link to review the publication )

Lung Cancer, 2016, 96:7-14

PubMed: 27133742 ( click the link to review the publication )

Sci Rep, 2016, 6:32705

PubMed: 27596239 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2016, 310(2-:L187-201

PubMed: 26589479 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2016, 54(1):51-9

PubMed: 26072676 ( click the link to review the publication )

Int J Oncol, 2016, 48(3):937-44

PubMed: 26783187 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0154874

PubMed: 27144281 ( click the link to review the publication )

J Physiol Biochem, 2016, 72(1):71-81

PubMed: 26714823 ( click the link to review the publication )

Nucl Med Biol, 2016, 43(10):612-24

PubMed: 27497236 ( click the link to review the publication )

Oncotarget, 2016, 7(31-:50161-50179

PubMed: 27367030 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Oncotarget, 2016, 7(50-:83514-83529

PubMed: 27835864 ( click the link to review the publication )

Am J Respir Crit Care Med, 2015, 192(4):455-67

PubMed: 26039104 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )
Oncotarget, 2015, 6(3):1569-81

PubMed: 25595912 ( click the link to review the publication )

Oncotarget, 2015, 6(26):22098-113

PubMed: 26061747 ( click the link to review the publication )

Nat Neurosci, 2014, 17(1):24-6

PubMed: 24241396 ( click the link to review the publication )

Front Genet, 2014, 5:170

PubMed: 24959172 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):477

PubMed: 24986540 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(4-:e00030

PubMed: 25505594 ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014,

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(9):1749-62

PubMed: 23804704 ( click the link to review the publication )

PLoS Negl Trop Dis, 2013,

PubMed: 23696913 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2013, 40(9):662-70

PubMed: 23819722 ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Mol Cancer Ther, 2011, 11(3):690-9

PubMed: 22238366 ( click the link to review the publication )

Cell Oncol , 2011, 34(1):33-44

PubMed: 21290212 ( click the link to review the publication )

Cell Death Differ, 2010, 17(9):1381-91

PubMed: 20300113 ( click the link to review the publication )

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

产品描述

靶点

VEGFR2 ^[1] (Cell-free assay)	VEGFR3 ^[1] (Cell-free assay)	LCK ^[1] (Cell-free assay)	FLT3 ^[1] (Cell-free assay)	VEGFR1 ^[1] (Cell-free assay)	点击更多
13 nM	13 nM	16 nM	26 nM	34 nM	点击更多

体外研究

BIBF1120对酪氨酸激酶受体如EGFR, HER2, InsR, IGF1R 或者细胞周期激酶 CDK1, CDK2 和CDK4抑制效果不大， IC50都大于1x10³nM。BIBF1120强抑制VEGF-刺激的HUVEC 和VEGF-刺激的HSMEC，EC50分别为9 和 7 nM。相反，BIBF1120 作用于FaDu, Calu-6 和Hela时EC50则大到几百倍。^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
SKOV3	MnHtSpVv[3Srb36gRZN{[Xl?	NELXNmc2KML3TR?=	NVvwNWpNOjRiaB?=	M4n5dWROW09?	NWfaT2c5cW6mdXPld{BiKHOrZ37p[olk[W62IHnuZ5Jm[XOnIHnuJJRp\SCycn;tc5RmeiCjY4Tpeol1cWW\|IH;mJGUu[2GmLNMgR2RJOSxiYX7kxsBETEh\|	NGe3cHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC2NVc1Pyd-Mk[wOlE4PDd:L3G+
A549	NWCw[I5LTnWwY4Tpc44hSXO\|YYm=	MoDlNk82KM7:TR?=	M4nablI1KGh?	MWHEUXNQ	MnHTbIF{KGFiZ3Xu[ZJidCCHTWSgdoV3\XK\|YXyg[YZn\WO2wrC=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4MUe0O{c,OjZyNkG3OFc9N2F-
T24	NX;UWVNoTnWwY4Tpc44hSXO\|YYm=	NV;HS5M1Oi93IN88US=>	MoTYNlQhcA>?	M3nIT2ROW09?	Mo\QbIF{KGFiZ3Xu[ZJidCCHTWSgdoV3\XK\|YXyg[YZn\WO2wrC=	MmS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyNkG3OFcoRjJ4ME[xO\|Q4RC:jPh?=
Mia-Paca2	MX\GeY5kfGmxbjDBd5NigQ>?	MkO5Nk82KM7:TR?=	M1zaOlI1KGh?	M1e0OmROW09?	NUK2W5B1cGG\|IHGg[4Vv\XKjbDDFUXQhemW4ZYLzZYwh\W[oZXP0xsA>	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB4MUe0O{c,OjZyNkG3OFc9N2F-
A549	M2HvbmZ2dmO2aX;uJGF{e2G7	M{PUWlAvODIkgKO1xsDPxE1?	MWeyOEBp	NV;3XZNsTE2VTx?=	NF;aO5lqdmS3Y3XzJHNHXFCGwrDtVm5CKGW6cILld5Nqd25iZH;z[UBl\XCnbnTlcpRtgQ>?	MmTyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NEOwNFUoRjJ3OESzNFA2RC:jPh?=
A549	Ml3OSpVv[3Srb36gRZN{[Xl?	M3vDeVAvODIkgKO1xsDPxE1?	M2fET\|czKGh?	M2LFdWROW09?	Mom3[Y5p[W6lZYOgV3AuTCCycn;0[YlvKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJiYYSgZ49v[2WwdILheIlwdnNib3[geZAhfG9iNdMg{txOyqB?	Mlj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6NEOwNFUoRjJ3OESzNFA2RC:jPh?=
A549	MXvGeY5kfGmxbjDBd5NigQ>?	NEXofnk2yqEQvF2=	MVSwMVEhcA>?	Mn\QSG1UVw>?	NGLGcZFqdmO{ZXHz[ZMhSVBvMTDhZ5RqfmG2aX;uJEBi\nSncjCzNEBucW5?	M4naU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OESzNFA2Lz5{NUi0N\|AxPTxxYU6=
Hep3B	M2X3NmNmdGxiVnnhZoltcXS7IFHzd4F6	NH\GTZUxNTJyIN88US=>	MWK0POKhcA>?		M{PSfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M4TVOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW3N\|k5Lz5{NE[1O\|M6QDxxYU6=
HepG2	M4m4N2NmdGxiVnnhZoltcXS7IFHzd4F6	MWOwMVIxKM7:TR?=	NH3sRWU1QMLiaB?=		MWnk[YNz\WG\|ZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NVOxR4VTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVc{QThpPkK0OlU4Ozl6PD;hQi=>
PLC5	M3v2bmNmdGxiVnnhZoltcXS7IFHzd4F6	NGDOUnQxNTJyIN88US=>	NH;TZVc1QMLiaB?=		MlnT[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	NV;sb4hWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVc{QThpPkK0OlU4Ozl6PD;hQi=>
HuH7	MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M1\kflAuOjBizszN	M3v0T\|Q5yqCq		M{nhfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7	M4jXdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW3N\|k5Lz5{NE[1O\|M6QDxxYU6=
SK-Hep1	MVfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NF7sVGIxNTJyIN88US=>	MljROFjDqGh?		NYS0S2Vt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIRwe2ViZHXw[Y5l\W62bIm=	NIjkfI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1O\|M6QCd-MkS2OVc{QTh:L3G+
Hep3B	M3jMOmFxd3C2b4Ppd{BCe3OjeR?=	M17jU\|AuOjBizszN	NGm5[Hc1QMLiaB?=		M4L6VYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiZH;z[UBl\XCnbnTlcpRtgQ>?	MmXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NUezPVgoRjJ2NkW3N\|k5RC:jPh?=
HepG2	NYPxPJNPSXCxcITvd4l{KEG\|c3H5	NFzDTmwxNTJyIN88US=>	NFHOXGI1QMLiaB?=		NIfXcFRqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHTvd4Uh\GWyZX7k[Y51dHl?	NXT3bJAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVc{QThpPkK0OlU4Ozl6PD;hQi=>
PLC5	NILxe4pCeG:ydH;zbZMhSXO\|YYm=	NVHafmNIOC1{MDFOwG0>	NHjSWmE1QMLiaB?=		NUXob2NzcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NV3TR4dURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2OVc{QThpPkK0OlU4Ozl6PD;hQi=>
HuH7	NHTlTVlCeG:ydH;zbZMhSXO\|YYm=	MnLiNE0zOCEQvF2=	MYC0POKhcA>?		Ml22bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCmb4PlJIRmeGWwZHXueIx6	M{j4UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW3N\|k5Lz5{NE[1O\|M6QDxxYU6=
SK-Hep1	MlHTRZBweHSxc3nzJGF{e2G7	NEjPeWYxNTJyIN88US=>	NFzpV441QMLiaB?=		NXTtXFVucW6mdXPld{Bk\WyuIHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	M3W1[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW3N\|k5Lz5{NE[1O\|M6QDxxYU6=
H1703	MlrIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVraT5FsUUN3ME2wMlA2KM7:TR?=	NHuzRmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{eyPVQxOyd-MkO3Nlk1ODN:L3G+
Sf9	NXW4foc3TnWwY4Tpc44h[XO\|YYm=		NXrTeIRDOjBibXnudy=>		NXq2[G9SUW6qaXLpeIlwdiCxZjDtc5V{\SCJU2St[pV{\WRiVlXHSnIzKGW6cILld5Nm\CCrbjDT[lkhcW6\|ZXP0JINmdGy\|IHHmeIVzKDJyIH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvODF\|IN88UU4>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3OUWyOEc,OTh3NUm1NlQ9N2F-
Sf9	MX7GeY5kfGmxbjDhd5NigQ>?		NUT5[mR7OjBibXnudy=>		MVXJcohq[mm2aX;uJI9nKGi3bXHuJGdUXC2odYPl[EBXTUeIUkKg[ZhxemW\|c3XkJIlvKFOoOTDpcpNm[3RiY3XscJMh[W[2ZYKgNlAhdWmwczDifUB{[2mwdHnscIF1cW:wIHPveY51cW6pLDDJR\|UxKD1iMD6wNlEh\|ryPLh?=	NFnqNHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1PVUzPCd-MUi1OVk2OjR:L3G+
NIH3T3	MYfGeY5kfGmxbjDhd5NigQ>?	M1i2b\|UxKG6P	NWjmeYFGOSCqch?=		NHS3XGNKdmirYnn0bY9vKG:oIG\FS2ZTOiC2cnHud4Zm[3SnZDDpckBud3W\|ZTDOTWg{XDNiY3XscJMh[XRiNUCgcm0hcW6ldXLheIVlKG[xcjCxJIhzKG2nYYP1doVlKGGodHXyJFMzKGi{czD3ZZNpd3W2IH\vcIxwf2WmIHL5JHZGT0Zic4TpcZVt[XSrb36g[o9zKDFyIH3pcpMh[nliV3XzeIVzdiCkbH;0eIlv\w>?	NGDKcZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1PVUzPCd-MUi1OVk2OjR:L3G+
HT-29	M1zQd2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NV7wWmtlPzJiaILz		MkTjRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iND65JO69VS5?	MlXaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzOUC2OVIoRjJ6MUmwOlUzRC:jPh?=
SKOV3	NFzCdoVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1r6Z\|czKGi{cx?=		NH3EVpBCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLU3Y{KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyPE44PiEQvF2u	NHzBSWU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEG5NFY2Oid-MkixPVA3PTJ:L3G+
BL21 (DE3)	M13ZSWZ2dmO2aX;uJIF{e2G7		M2Cwc\|MxKG2rboO=		MU\Jcohq[mm2aX;uJI9nKEirc{[teIFo\2WmIF3FUGsh[2G2YXz5eIlkKGSxbXHpckApOSC2bzCzOFAhemW\|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV\|KTDj[YxteyC3c3nu[{BD[2xvR1ygZZMhe3Wkc4TyZZRmKG2nYYP1doVlKGGodHXyJFMxKG2rboOgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iOzKSXVHUVEBjgSCuaYH1bYQhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFvpJF0hOC5yMEW2JO69VS5?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MU[wO{c,Ojh\|NUG2NFc9N2F-
BL21 (DE3)	NInFR2hHfW6ldHnvckBie3OjeR?=		MYezNEBucW6\|		MoLzTY5pcWKrdHnvckBw\iCKaYO2MZRi\2enZDDNSWxMKGOjdHHsfZRq[yCmb33hbY4hMDFidH:gN\|QxKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFLMNlEhMESHMzmgZ4VtdHNidYPpcochSmOuLVfMJIF{KHO3YoP0doF1\SCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIlvKHC{ZYPlcoNmKG:oIGvnZY1u[TN{UG3BWHAh[nlibHnxeYllKHOlaX70bYxt[XSrb36gZ492dnSrbnegcYV1cG:mLDDJR\|UxKD1iMD6wOFMh\|ryPLh?=	NGjDWJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NVYxPyd-MkizOVE3ODd:L3G+
HT-29	MYXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MU[3NkBpenN?		M1f4[mFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGStNlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuPFMh\|ryPLh?=	NGG2TXo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEiyOlA5PCd-Mki4NlYxQDR:L3G+
MCF7	NW\XSlFvSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MknGO\|IhcHK\|		M120bWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iOD6yPEDPxE1w	MnPPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh6Mk[wPFQoRjJ6OEK2NFg1RC:jPh?=
A549	NYDKbolISW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NHHrbHg4OiCqcoO=		NX3NUWFPSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyNk43OiEQvF2u	M3r2e\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OEK2NFg1Lz5{OEiyOlA5PDxxYU6=
NIH/3T3	M4nQVWZ2dmO2aX;uJIF{e2G7		MX20NkBpenN?		NVfhXFdNUW6qaXLpeIlwdiCxZjDQSGdHWiCrbjDtc5V{\SCQSVivN3Q{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDy[YNwdWKrbnHueEBpfW2jbjDQSGdHNUKELXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHHmeIVzKDR{IHjyd{BjgSClZXzsJJRqfGW{IEm2JIFyfWWxdYOgc45mKHOxbIX0bY9vKGKjc3XkJIF{e2G7LDDJR\|UxKD1iMD6wPFUh\|ryPLh?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF3MkC0OUc,OjlzNUKwOFU9N2F-
Sf9	M3XVfGZ2dmO2aX;uJIF{e2G7				NVjmcZk1UW6qaXLpeIlwdiCxZjDoeY1idiCYRVfGVlIh\XiycnXzd4VlKGmwIGPmPUBk\WyuczygTWM2OCB;IECuNFA2KM7:TT6=	NHPHO3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWyNlQ3PSd-MUm1NlI1PjV:L3G+
NIH3T3	NVnQR5dYTnWwY4Tpc44h[XO\|YYm=		M1jsdVEhcHJ?		MUfJcohq[mm2aX;uJI9nKF[HR1[td5RqdXWuYYTl[EBpfW2jbjDWSWdHWjJicHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDtc5V{\SCQSVizWFMh[2WubIOgdJJmfHKnYYTl[EBnd3JiMTDodkBu\WG\|dYLl[EA{OiCqcoOgZYZ1\XJiZIL1[{Bld3OnIHL5JIludXWwb4Dy[YNqeGm2YYTpc44h[mG\|ZXSgdJVte2VvY3jhd4Uh\XiyZYLpcYVvfA>?	M3f5TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUKyOFY2Lz5zOUWyNlQ3PTxxYU6=
BRP	NFrhc3RCeG:ydH;zbZMh[XO\|YYm=				MmS3TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDCVnAh[2WubIOgZZN{\XO\|ZXSgZZMh[2G\|cHHz[U0{KGOuZXH2ZYdm	NIPuT3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWyNlQ3PSd-MUm1NlI1PjV:L3G+
BRP	NFPmcIZCdnSrYX7nbY9o\W6rYzDhd5NigQ>?				M1nH[WFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IFLSVEBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjDifUBcO0ifdHj5cYllcW6nIHnuZ49zeG:{YYTpc44h[XO\|YYm=	NXvOPHlIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1NlI1PjVpPkG5OVIzPDZ3PD;hQi=>
TC32	MXXxTHRUKGG\|c3H5				M1r6SJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	M{HGfpFJXFNiYYPzZZk>				MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	NFm3Wlc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	NEPrNG9yUFSVIHHzd4F6				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M2qxS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	NHLEPYRyUFSVIHHzd4F6				NYi1O5lXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	NHvxeHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-37	M{O0SpFJXFNiYYPzZZk>				M3;jeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	M{\JOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	MYLxTHRUKGG\|c3H5				M3zNZ5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz	NG\UdIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NW[4dJVFeUiWUzDhd5NigQ>?				NYDSPZgzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=>	NX\WV2VJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
OHS-50	MlrzdWhVWyCjc4PhfS=>				NV7HepJweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	MkS0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NVPOeGlPeUiWUzDhd5NigQ>?				NHLrSXdyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBNSU5vNTDj[Yxtew>?	NF3JVlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MY\xTHRUKGG\|c3H5				NXTFeZI{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	NGTpd2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	MkfwdWhVWyCjc4PhfS=>				NIPTSpZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUni0NUBk\Wyucx?=	Mk\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	NXLm[3NreUiWUzDhd5NigQ>?				MX3xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDNS{A3OyBqNj3US{BTMSClZXzsdy=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh30	MYHxTHRUKGG\|c3H5				M36ycpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	M3G4VlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
U-2 OS	NX\5bW43eUiWUzDhd5NigQ>?				MXTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM>	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NIDUOZNyUFSVIHHzd4F6				NU\CNo9SeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	MoTHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	Mnq4dWhVWyCjc4PhfS=>				NEXJeZhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	NIC0Zoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MXLxTHRUKGG\|c3H5				NGC1OlFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NEXNb3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	Ml\mdWhVWyCjc4PhfS=>				M4nyS5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	MkTsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	Mo\TdWhVWyCjc4PhfS=>				NFjUZZpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO=	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB1643	NG\YN4hyUFSVIHHzd4F6				M4\JdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG5DOTZ2MzDj[Yxtew>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NV6xV4JHeUiWUzDhd5NigQ>?				MlT4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	MnjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	NIfMO4xyUFSVIHHzd4F6				M4fUXpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	NFfFbFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NUHFbI8yeUiWUzDhd5NigQ>?				MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFE5KGOnbHzz	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Collagen 1a1; PubMed: 26072676 Am J Respir Cell Mol Biol (A and B) IPF fibroblasts were treated with increasing doses of nintedanib (0.5, 1, or 2 μM) (A) or nintedanib (2 μM) for increasing durations (24, 48, or 72 h) (B). Expression of fibronectin and collagen 1a1 was evaluated by Western immunoblotting. p-SMAD3 / SMAD3 / p-p38 MAPK / p38 MAPK ; PubMed: 26072676 Am J Respir Cell Mol Biol IMR-90 fibroblasts were serum starved overnight and cotreated with or without TGF-β1 (2.5 ng/ml) and increasing doses of nintedanib (0.5, 1, and 2 μM) for 1 hour. Expression of pS423/425-SMAD3, SMAD3, pT180/Y182-p38 mitogen-activated protein kinase (MAPK), and p38 MAPK was evaluated by Western blotting. Cyclin A / Cyclin D1 / Cyclin E / CDK2 / CDK4 / CDK6; PubMed: 29934570 Sci Rep Western blot based detection of cell cycle associated molecules viz., Cyclins A, D1 and E, and CDKs 2, 4 and 6 in PC3 cells after 72 hours of Nintedanib treatment. p-EGFR / FGFR1 / p-AKT / AKT / p-ERK / ERK; PubMed: 27581340 Cancer Sci Effects of nintedanib on FGFR1, ERK, and AKT phosphorylation in FGFR1 CNG‐positive lung squamous cell carcinoma cell lines. H520 and LK‐2 cells were incubated for 6 h in the presence of the indicated concentrations of nintedanib, after which cell lysates (25 μg soluble protein) were subjected to immunoblot analysis with antibodies to the indicated proteins.	26072676 29934570 27581340
Immunofluorescence	Vimentin / E-cadherin ; PubMed: 29934570 Sci Rep Immunoflouresence staining for Vimentin (green) and E-cadherin (red) in DMSO control and 2.5 µM Nintedanib treated PC3 cells after 72 h of incubation. Representative flourescent pictures are shown at 600X. DAPI: 4′,6-diamidino-2-phenylindole.	29934570

体内研究

在小鼠的Fadu 移植瘤中，按鼠体重，每千克处理100mg BIBF1120,结果显示肿瘤血管密度降低76%。BIBF1120 作用于移植瘤模型Caki-1, HT-29, SKOV-3, Calu6 和PAC-120同样有显著的抑制效果。BIBF1120已用于治疗多种癌症，包括：非小细胞肺癌，前列腺癌，卵巢癌，及结肠直肠癌。且BIBF1120目前处于二期临床实验阶段。^[1]

激酶实验：^[1]	- 合并激酶实验: VEGFR-2的胞质酪氨酸激酶域克隆到pFastBac载体上，与谷胱甘肽巯基转移酶 (GST)相融合。 GST融合蛋白在SF-9昆虫细胞中表达，用重元素萃取分离法提取。HEPEX萃取液包括20 mM HEPES （pH 为7.4）, 100 mM NaCl, 10 mM ss-甘油磷酸盐, 10 mM 聚硝基磷酸单苯酯, 30mM NaF, 5 mM EDTA, 5% 甘油, 1% Triton X-100, 1 mM Na₃VO₄, 0.1% SDS, 0.5μg/ml 抑肽素A, 2.5 μg/ml 3,4-二氯异香豆素(丝氨酸蛋白酶的不可逆抑制剂), 2.5 μg/ml反式-环氧琥珀酰-L-亮氨酰-L-氨基丁烷, 20 KIU/ml 抑肽酶, 2 μg/ml 亮抑肽酶, 1 mM苯甲脒，和0.002% PMSF。谷氨酸和酪氨酸按4:1比例随机组成的聚合物作为基底物，每组50ul的反应液包括5 % DMSO, 40 mM HEPES （pH 为 7.4）, 5 mM MgCl₂, 5 mM MnCl₂, 0.5 mg/ml 聚谷氨酸/酪氨酸, 0.05% Triton X-100, 100 μM ATP, 1 μCi [γ-³³P]ATP ，和 10 μl酶制剂。实验在室温下进行20分钟，最后加入10 μl 5 % H₃PO₄终止反应。沉淀物转移到GF/B 过滤器中，使用与96孔过滤器相配的万能采集器收集。通过闪烁计数器测定混合物的放射能。
细胞实验：^[1]	- 合并 Cell lines: HUVEC, HUASMC,和BRP细胞系 Concentrations: 50 nM Incubation Time: 2小时 Method: 不同的肿瘤细胞系在96孔板上培养24小时。然后加入不同浓度的BIBF1120，处理72小时。通过Alamar-Blue染色的荧光强度测试EC50值。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 雌性无胸腺NMRI-nu/nu鼠 Dosages: 100 mg/kg Administration: 口服处理 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	6 mg/mL (11.11 mM)
	Ethanol	3 mg/mL (5.55 mM)
	Water	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5% DMSO+40% PEG 300+2% Tween 80+ddH2O	0.25mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Nintedanib (BIBF 1120) SDF

分子量	539.62
化学式	C₃₁H₃₃N₅O₄
CAS号	656247-17-5
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	Intedanib, Vargatef, Ofev

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04525547	Not yet recruiting	Drug: Nintedanib	Idiopathic Pulmonary Fibrosis	Boehringer Ingelheim	December 31 2020	--
NCT04541680	Recruiting	Drug: Nintedanib 150 MG [Ofev]\|Other: Placebo	SARS-Cov-2 Induced Pulmonary Fibrosis	Assistance Publique - Hôpitaux de Paris\|Boehringer Ingelheim	October 29 2020	Phase 3
NCT03283007	Recruiting	Drug: Nintedanib\|Drug: Placebo	Lung-transplant Recipients	Assistance Publique - Hôpitaux de Paris	October 30 2019	Phase 3
NCT03958071	Completed	Drug: Nintedanib\|Drug: Pirfenidone\|Other: Untreated Cohort	Idiopathic Pulmonary Fibrosis	Boehringer Ingelheim	February 1 2019	--
NCT03710824	Recruiting	Drug: Nintedanib	Idiopathic Pulmonary Fibrosis	Boehringer Ingelheim	February 28 2019	--

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

选择性强的VEGFR抑制剂

Vandetanib (ZD6474) : VEGFR2-selective, IC50=40 nM.
活性最高的VEGFR抑制剂

Cabozantinib (XL184, BMS-907351) : VEGFR2, IC50=0.035 nM.
FDA批准的VEGFR抑制剂

Axitinib : Approved by FDA for Renal Cell Carcinoma.
经典的VEGFR抑制剂

Dovitinib (TKI-258, CHIR-258) : Multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM.

研究领域

产品类型

定制您的化合物库

Nintedanib (BIBF 1120)

客户使用Selleck生产的Nintedanib (BIBF 1120)发表文献87篇：

产品安全说明书

VEGFR抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Nintedanib (BIBF 1120) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2021-01-06)

技术支持

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

相关VEGFR产品